Moberg Pharma Unveils Terclara Now Available in Norway
Moberg Pharma Launches Terclara in Norway
Moberg Pharma AB (OMX: MOB) and its partner, Allderma, are excited to announce that Terclara (MOB-015) is officially being launched in Norway. This step is a significant part of their strategy to expand their market presence in Europe and build upon the success already achieved in Sweden, where Terclara holds the position of market leader.
Successful Strategy from Sweden Guides Launch
Following the announcement of a new supplier for terbinafine, Moberg Pharma is well-prepared to proceed with the launch in Norway. The new supplier was necessary to ensure that the product could be made available this year. With the procurement of sufficient terbinafine, the company is confidently moving forward with Terclara's rollout.
The experience gained from the Swedish market has provided vital insights that will assist in successfully entering the Norwegian arena. The launch will adapt similar strategies used previously, ensuring a competitive edge. The first deliveries to pharmacies are on schedule for February, accompanied by targeted information campaigns aimed at pharmacy staff and healthcare professionals. Simultaneously, a consumer marketing effort will grow more robust leading up to the peak season, known for heightened demand for nail fungus treatments.
Confidence from Leadership
Anna Ljung, CEO of Moberg Pharma AB, expressed enthusiasm regarding the expansion: "The launch of Terclara in Norway is a significant milestone for our European market penetration. Allderma has shown exceptional capability, achieving strong sales results in Sweden, and we are optimistic they will replicate this success in Norway as well."
Additionally, Mimmi Frölén, CEO of Allderma, remarked, "Starting this launch in Norway fills us with pride. The wisdom and experience from Sweden have been crucial, and we trust Terclara will establish a strong foothold in Norway’s market. We are excited about the potential that lies ahead. "
About Moberg Pharma
Moberg Pharma AB is a Swedish pharmaceutical company dedicated to commercializing innovative products based on well-established drugs. Its flagship drug, MOB-015, is a groundbreaking topical treatment for onychomycosis (nail fungus), currently approved across 13 European Union countries. In Sweden, MOB-015 is marketed as Terclara and is widely available in pharmacy chains. Phase 3 clinical trials involving over 800 patients indicate that this product has serious potential to dominate the market for nail fungus treatments.
Headquartered in Sweden, Moberg Pharma caters to various regions, including Europe and Canada, having established commercial agreements with partners in these areas. The shares of Moberg Pharma are listed on the Nasdaq Stockholm under the ticker MOB.
About Allderma Pharmaceuticals
Allderma Pharmaceuticals is also a Swedish company that has been dedicated to developing, selling, and marketing over-the-counter and self-care products since 2001. Their expertise particularly shines in dermatology, addressing a variety of treatment areas. Founded by Hans Svartholm, the company emphasizes the importance of finding safe and effective solutions for common skin conditions. Their ongoing commitment involves substantial investments in educating healthcare providers, pharmacists, and consumers about their products. Since 2020, Allderma has been a part of 3iM Invest AB’s Consumer Healthcare investment segment.
Frequently Asked Questions
What is the significance of the Terclara launch in Norway?
The launch marks a strategic expansion for Moberg Pharma and Allderma, building on their success in Sweden and enhancing their presence in the European market.
Who are the key players in this launch?
Moberg Pharma and Allderma are at the forefront of this launch, with leadership provided by Anna Ljung and Mimmi Frölén respectively, indicating a strong partnership.
What is Terclara used for?
Terclara (MOB-015) is a topical treatment specifically developed for onychomycosis, commonly known as nail fungus.
How has the previous launch in Sweden influenced this rollout?
Insights and strategies from the Swedish market are being replicated in Norway to maximize the chances of success during the launch.
Where can you find Moberg Pharma's products?
Moberg Pharma’s products, including Terclara, are available in pharmacies throughout Sweden and will soon be accessible in Norwegian pharmacies following this launch.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
